Please ensure Javascript is enabled for purposes of website accessibility

Eli Lilly Teams With Indiana Health Agency to Provide Speedy Coronavirus Testing There

By Eric Volkman - Mar 19, 2020 at 10:07AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The pharmaceutical company is moving quickly to set up rapid free SARS-CoV-2 testing for residents of its home state.

Eli Lilly (LLY 0.51%) is linking up with the Indiana State Department of Health (ISDH) to rapidly expand and accelerate testing for the SARS-CoV-2 coronavirus in its home state. In a press release issued on Wednesday, the company said that it will soon begin offering free coronavirus tests to Indiana residents.


Eli Lilly employee conducting research.

Image source: Eli Lilly

Since its founding almost a century and a half ago, Eli Lilly has been based in Indiana's capital city of Indianapolis. The pharmaceutical giant will utilize its specialized research laboratories there to test samples collected by healthcare facilities across the state. 

"Assuming the company can continuously access required diagnostic reagents, this should start to expand the state's ability to conduct testing and receive a timely diagnosis of individuals who suspect they may be carrying the virus," Lilly said in its press release on the matter.

"As Lilly's testing capacity expands, Lilly and ISDH will work together to maximize the impact of broader testing," the company added.

The federal government has come under fire for not being better prepared to test for the coronavirus. As a result, a number of healthcare companies and state and local governments have taken it upon themselves to address the shortage. In its press release, Lilly said its testing plan had the "support" of the U.S. Food and Drug Administration.

Lilly is also working on setting up drive-through testing that would allow it to conduct the activity outside of healthcare facilities. It did not provide details about that, nor did it offer a time frame for when such a testing site might be up and running.

The pharmaceutical company's shares held up quite well on Wednesday, considering the decline of the broader stock market. They essentially traded sideways on the day.


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Eli Lilly and Company Stock Quote
Eli Lilly and Company
$327.27 (0.51%) $1.65

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.